Eli Lilly’s Omvoh (mirikizumab-mrkz) helped patients with moderately to severely active ulcerative colitis and Crohn’s disease achieve multiple treatment goals simultaneously after one year, according to new analyses from the company’s Phase 3 clinical trial programmes.

 

The findings showed that 27.7% of Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, while 20.4% of those with Crohn’s disease achieved corticosteroid-free deep remission.

 

The results, drawn from the LUCENT-2 and VIVID-1 trials, point to a broader approach to inflammatory bowel disease (IBD) treatment — one that looks beyond symptom relief to assess intestinal inflammation, objective measures of disease activity and patients’ quality of life.

 

Importantly, the outcomes were also observed in patients who had previously failed biologic treatments, a group that often faces greater challenges in managing the disease.

 

In the ulcerative colitis analysis, 35.3% of patients had a history of biologic treatment failure. In the Crohn’s disease analysis, the proportion was 48.6%.

 

“Treatment in inflammatory bowel disease is often measured one endpoint at a time. These new data show that patients treated with Omvoh achieved multiple treatment goals simultaneously at one year, including those with prior biologic failure, and were more likely to report better quality of life,” said Anabela Cardoso, senior vice president, Lilly Immunology Medical Affairs.

 

“These findings reinforce the impact that Omvoh can have for people living with ulcerative colitis and Crohn's disease and show that a higher bar for disease control is achievable.”

 

The LUCENT-2 analysis assessed patients with ulcerative colitis who responded to Omvoh during the initial LUCENT-1 induction study and were subsequently assigned to continue Omvoh or receive placebo during maintenance treatment.

 

Comprehensive disease control — a composite measure incorporating clinical remission, histologic remission, normalized inflammatory biomarkers and freedom from corticosteroid use — was achieved by 27.7% of patients continuing Omvoh, compared with 14% receiving placebo.

 

Among patients with prior biologic treatment failure, 23.4% of those receiving Omvoh achieved the outcome, compared with 9.4% in the placebo group.

 

The analysis also found a strong association between comprehensive disease control and improved quality of life. Among Omvoh-treated patients who achieved the composite outcome, 91.1% also achieved remission on the Inflammatory Bowel Disease Questionnaire (IBDQ), a validated measure of health-related quality of life. The corresponding figure was 65.2% among patients who did not achieve comprehensive disease control.

 

Patients reaching the composite endpoint were also more likely to report no to minimal bowel urgency and greater improvements in work productivity.

 

Lilly said Omvoh is the first IL-23p19 inhibitor evaluated for comprehensive disease control in ulcerative colitis, reflecting a treatment approach that combines several measures of disease activity rather than relying on a single endpoint.

 

In the VIVID-1 analysis, 20.4% of patients treated with Omvoh achieved corticosteroid-free deep remission after one year, compared with 2% of those receiving placebo.

 

The composite endpoint required patients to achieve clinical remission and endoscopic remission while remaining off corticosteroids for at least 12 weeks before the one-year assessment.

 

Among patients with prior biologic treatment failure, 15.7% of those receiving Omvoh achieved corticosteroid-free deep remission. No patients in the placebo group achieved the outcome.

 

Quality-of-life findings followed a similar pattern. Among Omvoh-treated patients who achieved corticosteroid-free deep remission, 88.1% also achieved IBDQ remission, compared with 51% of those who did not reach the composite endpoint.

 

The findings suggest that patients who achieve deeper control of their disease may also be more likely to report improvements in their day-to-day wellbeing, although the post-hoc analyses demonstrate associations rather than proving that one outcome causes the other.

 

The new analyses reflect a growing emphasis on multidimensional treatment targets in IBD management, bringing together patient-reported symptoms, clinical assessments and objective evidence of inflammation.

 

“Inflammatory bowel disease is complex, and understanding treatment impact requires a broader view than any single endpoint can provide. These endpoints reflect a meaningful shift in how we define treatment success,” said Stefan Schreiber, University Hospital Schleswig-Holstein, Christian-Albrecht University of Kiel.

 

“Across the LUCENT and VIVID programs, Omvoh-treated patients achieved multidimensional treatment outcomes, including comprehensive disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease. Importantly, these outcomes were also observed in patients with prior biologic failure.”

 

Previous real-world studies have associated improvements across multiple dimensions of IBD with lower risks of disease flares, corticosteroid use, hospitalisation and surgery over time.

 

The latest findings add to the evidence supporting treatment targets that extend beyond clinical remission alone, although further research will be needed to establish how these composite outcomes translate into long-term patient benefits.